Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Cash & Equivalents (2021 - 2025)

Historic Cash & Equivalents for Prime Medicine (PRME) over the last 5 years, with Q3 2025 value amounting to $71.4 million.

  • Prime Medicine's Cash & Equivalents fell 3948.31% to $71.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.4 million, marking a year-over-year decrease of 3948.31%. This contributed to the annual value of $182.5 million for FY2024, which is 33891.86% up from last year.
  • Per Prime Medicine's latest filing, its Cash & Equivalents stood at $71.4 million for Q3 2025, which was down 3948.31% from $53.8 million recorded in Q2 2025.
  • In the past 5 years, Prime Medicine's Cash & Equivalents ranged from a high of $200.7 million in Q3 2021 and a low of $41.6 million during Q4 2023
  • For the 5-year period, Prime Medicine's Cash & Equivalents averaged around $110.9 million, with its median value being $94.2 million (2024).
  • Its Cash & Equivalents has fluctuated over the past 5 years, first tumbled by 7784.14% in 2023, then soared by 33891.86% in 2024.
  • Over the past 5 years, Prime Medicine's Cash & Equivalents (Quarter) stood at $185.4 million in 2021, then increased by 1.19% to $187.6 million in 2022, then crashed by 77.84% to $41.6 million in 2023, then soared by 338.92% to $182.5 million in 2024, then plummeted by 60.87% to $71.4 million in 2025.
  • Its last three reported values are $71.4 million in Q3 2025, $53.8 million for Q2 2025, and $91.9 million during Q1 2025.